Get the Stockscreener App
41.83
6.28%
2.47
After Hours:
41.71
-0.12
-0.29%
Moderna Inc stock is traded at $41.83, with a volume of 11.87M.
It is up +6.28% in the last 24 hours and up +39.95% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$39.36
Open:
$41.6
24h Volume:
11.87M
Relative Volume:
1.07
Market Cap:
$16.34B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-4.7915
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+21.95%
1M Performance:
+39.95%
6M Performance:
+30.47%
1Y Performance:
+23.90%
1-Day Range:
$40.55
$42.39
1-Week Range:
$32.37
$42.39
52-Week Range:
$22.28
$45.40
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.83 | 15.38B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer - Finviz
Moderna (NASDAQ:MRNA) Shares Gap UpStill a Buy? - MarketBeat
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026 - FinancialContent
Arbutus falls as patent row with Moderna hits EU snag (ABUS) - Seeking Alpha
Moderna's Q4 2025 Earnings: What to Expect - Barchart.com
Best Biotech Stocks To Keep An Eye OnJanuary 15th - MarketBeat
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Analysts Set Expectations for Moderna FY2030 Earnings - MarketBeat
Non-covid mRNA Vaccine and Therapeutics Market Exclusive Report on the Latest Revenue and Future Scope - openPR.com
Aug Drivers: Is Moderna Inc a turnaround story2025 Trading Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Moderna projects 10% growth next year; lifts outlook for year-end liquidity - MSN
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot - FinancialContent
Moderna (MRNA) Stock: Biotech Leader Surges 30% on Updated Guidance - Blockonomi
Moderna (MRNA) rockets 17% on strong preliminary FY25 results - MSN
Moderna (MRNA) Rockets 17% on Strong Preliminary FY25 Results - Insider Monkey
Moderna Inc.: From Pandemic Phenomenon to mRNA Platform Powerhouse - AD HOC NEWS
Building Companies Like Experiments: The Flagship Pioneering Model - Citeline News & Insights
Trending tickers: Nvidia, Intel, Moderna, BP and Vistry - Yahoo Finance UK
Moderna (MRNA) Stock: Biotech Breaks Out With 30% Rally in 2026 - CoinCentral
Moderna 2026 at JPM 2026: Projects $1.9B Revenue and Eyes Vaccine Approvals - geneonline.com
Intel, Moderna, Adobe, BitMine Immersion And Strategy: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target - BioPharma Dive
Moderna Eyes Higher Revenue and Strategic Approvals at J.P. Morgan Event - timothysykes.com
Adobe stock downgraded, Moderna surges on upbeat guidance - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 7.1%Still a Buy? - MarketBeat
Moderna rallies after projecting better-than-expected 2025 sales - Sherwood News
Why Moderna Stock Strength Is Only Beginning: Technical Analysis - Barron's
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
Moderna (MRNA) Shares Surge by Nearly 13% - GuruFocus
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday - Benzinga
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next - TechStock²
Moderna jumps 12% after 2025 projections - breakingthenews.net
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA) - Seeking Alpha
Moderna updates 2025 outlook and highlights pipeline progress - The Globe and Mail
Moderna says possible allergic reactions to Covid-19 vaccine under investigation - The Daily Star
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Providence Journal
Moderna chair says US assault on science is just beginning - The Daily Gazette
Commonwealth Fusion Systems Appoints Stephane Bancel, Moderna CEO, to Its Board of Directors - energynews
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape - The Chronicle-Journal
Moderna Chair Says US Assault on Science Is Just Beginning - Bloomberg.com
Commonwealth Fusion Systems Appoints Stephane Bancel To Board - citybiz
Moderna expects 2025 revenue of $1.9B, above guidance - Proactive financial news
Aug Decliners: Should you avoid Moderna Inc stock right now2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating - marketscreener.com
Why Moderna Stock Is Dropping After Good News - Barron's
Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year - marketscreener.com
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast - BioSpace
Moderna says its expects $1.9 billion in 2025 sales amid better-than-expected vaccination rate - Sherwood News
Moderna raises its forecasts and the stock rises before the opening of the US market - المتداول العربي
Moderna sees sales boost as COVID shots beat expectations - The Detroit News
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AFEYAN NOUBAR | Director |
Dec 11 '25 |
Sale |
29.48 |
23,853 |
703,306 |
3,924 |
| Bancel Stephane | Chief Executive Officer |
Dec 11 '25 |
Option Exercise |
10.90 |
688,073 |
7,499,996 |
6,181,970 |
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):